- Home
- EDIT vs NVCT Comparison
EDIT vs NVCT Comparison
Compare EDIT & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- NVCT
- Stock Information
- Founded
- EDIT 2013
- NVCT 2020
- Country
- EDIT United States
- NVCT United States
- Employees
- EDIT N/A
- NVCT N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- EDIT Health Care
- NVCT Health Care
- Exchange
- EDIT Nasdaq
- NVCT Nasdaq
- Market Cap
- EDIT 156.5M
- NVCT 184.9M
- IPO Year
- EDIT 2016
- NVCT 2022
- Fundamental
- Price
- EDIT $2.25
- NVCT $8.13
- Analyst Decision
- EDIT Buy
- NVCT Strong Buy
- Analyst Count
- EDIT 13
- NVCT 3
- Target Price
- EDIT $6.73
- NVCT $17.00
- AVG Volume (30 Days)
- EDIT 2.4M
- NVCT 96.4K
- Earning Date
- EDIT 08-06-2025
- NVCT 08-05-2025
- Dividend Yield
- EDIT N/A
- NVCT N/A
- EPS Growth
- EDIT N/A
- NVCT N/A
- EPS
- EDIT N/A
- NVCT N/A
- Revenue
- EDIT $35,837,000.00
- NVCT N/A
- Revenue This Year
- EDIT N/A
- NVCT N/A
- Revenue Next Year
- EDIT N/A
- NVCT N/A
- P/E Ratio
- EDIT N/A
- NVCT N/A
- Revenue Growth
- EDIT N/A
- NVCT N/A
- 52 Week Low
- EDIT $0.91
- NVCT $4.44
- 52 Week High
- EDIT $6.05
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- EDIT 63.76
- NVCT 37.24
- Support Level
- EDIT $2.05
- NVCT $8.79
- Resistance Level
- EDIT $2.55
- NVCT $9.30
- Average True Range (ATR)
- EDIT 0.23
- NVCT 0.50
- MACD
- EDIT 0.03
- NVCT -0.11
- Stochastic Oscillator
- EDIT 66.29
- NVCT 12.43
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.